{
  "source": "PA-Notification-Mavyret.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1231-9\nProgram Prior Authorization/Notification\nMedication Mavyret® (glecaprevir/pibrentasvir)\nP&T Approval Date 9/2017, 11/2018, 11/2019, 3/2020, 3/2021, 8/2021, 8/2022, 8/2023,\n8/2024\nEffective Date 11/1/2024\n1. Background:\nMavyret is a fixed-dose combination of glecaprevir, a hepatitis C virus (HCV) NS3/4A protease\ninhibitor, and pibrentasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult\nand pediatric patients 3 years and older with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6\ninfection without cirrhosis and with compensated cirrhosis (Child-Pugh A). Mavyret is also\nindicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype\n1 infection, who previously have been treated with a regimen containing an HCV NS5A\ninhibitor or an NS3/4A protease inhibitor, but not both.1\n2. Coverage Criteriaa:\nA. For the treatment of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection in treatment-\nnaïve patients without cirrhosis, or with compensated cirrhosis, Mavyret will be approved\nbased on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection\n-AND-\n2. Patient is treatment-naïve\n-AND-\n3. One of the following:\na. Patient is without cirrhosis\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n4. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 8 weeks.\nB. For the treatment of chronic hepatitis C genotype 1, 2, 4, 5 or 6 infection in patients who are\ntreatment-experienced with regimens containing interferon, pegylated interferon, ribavirin,\n© 2024 UnitedHealthcare Services Inc.\n1\nand/or Sovaldi (sofosbuvir) without cirrhosis, Mavyret will be approved based on all of the\nfollowing criteri",
    "ining interferon, pegylated interferon, ribavirin,\n© 2024 UnitedHealthcare Services Inc.\n1\nand/or Sovaldi (sofosbuvir) without cirrhosis, Mavyret will be approved based on all of the\nfollowing criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 2, 4, 5 or 6 infection\n-AND-\n2. Patient has prior treatment experience with a regimen including at least one of the\nfollowing:\na. Interferon (e.g., Intron-A)\nb. Pegylated interferon (e.g., Pegasys, PegIntron)\nc. Ribavirin (e.g., Rebetol)\nd. Sofosbuvir (e.g., Sovaldi)\n-AND-\n3. Patient has no prior treatment experience with any of the following regimens:\na. HCV NS3/4A protease inhibitor [e.g., Incivek (teleprevir), Victrelis (boceprevir),\nViekira (dasabuvir/ombitasvir/ paritaprevir/ritonavir), Zepatier\n(elbasvir/grazoprevir)]\nb. HCV NS5A inhibitor [e.g., Daklinza (daclatasvir), Epclusa (sofosbuvir/velpatasvir),\nHarvoni (ledipasvir/sofosbuvir), Viekira (dasabuvir/ombitasvir/\nparitaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n4. Patient is without cirrhosis\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 8 weeks.\nC. For the treatment of chronic hepatitis C genotype 1, 2, 4, 5 or 6 infection in patients who are\ntreatment-experienced with regimens containing interferon, pegylated interferon, ribavirin,\nand/or Sovaldi (sofosbuvir) with cirrhosis, Mavyret will be approved based on all of the\nfollowing criteria:\n1. Diagnosis of chronic hepatitis C genotype 1, 2, 4, 5 or 6 infection\n-AND-\n2. Patient has prior treatment experience with a regimen including at least one of the\n© 2024 UnitedHealthcare Services Inc.\n2\nfollowing:\na. Interferon (e.g., Intron-A)\nb. Pegylated interferon (e.g., Pegasys, PegIntron)\nc. Ribavirin (e.g., Rebetol)\nd. Sofosbuvir (e.g., Sovaldi)\n-AND-\n3. Patient has no prior treatment e",
    "Inc.\n2\nfollowing:\na. Interferon (e.g., Intron-A)\nb. Pegylated interferon (e.g., Pegasys, PegIntron)\nc. Ribavirin (e.g., Rebetol)\nd. Sofosbuvir (e.g., Sovaldi)\n-AND-\n3. Patient has no prior treatment experience with any of the following regimens:\na. HCV NS3/4A protease inhibitor [e.g., Incivek (teleprevir), Olysio (simeprevir),\nVictrelis (boceprevir), Viekira (dasabuvir/ombitasvir/ paritaprevir/ritonavir),\nZepatier (elbasvir/grazoprevir)]\nb. HCV NS5A inhibitor [e.g., Daklinza (daclatasvir), Epclusa (sofosbuvir/velpatasvir),\nHarvoni (ledipasvir/sofosbuvir), Viekira (dasabuvir/ombitasvir/\nparitaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n4. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 12 weeks.\nD. For the treatment of chronic hepatitis C genotype 3 infection in patients who are treatment-\nexperienced with regimens containing interferon, pegylated interferon, ribavirin, and/or\nSovaldi (sofosbuvir), who are without cirrhosis or have compensated cirrhosis, or is a liver\nor kidney transplant recipient, Mavyret will be approved based on all of the following\ncriteria:\n1. Diagnosis of chronic hepatitis C genotype 3 infection\n-AND-\n2. Patient has prior treatment experience with a regimen including at least one of the\nfollowing:\na. Interferon (e.g., Intron-A)\nb. Pegylated interferon (e.g., Pegasys, PegIntron)\nc. Ribavirin (e.g., Rebetol)\nd. Sofosbuvir (e.g., Sovaldi)\n© 2024 UnitedHealthcare Services Inc.\n3\n-AND-\n3. Patient has no prior treatment experience with any of the following regimens:\na. HCV NS3/4A protease inhibitor [e.g., Incivek (teleprevir), Olysio (simeprevir),\nVictrelis (boceprevir), Viekira (dasabuvir/ombitasvir/ paritaprevir/ritonavir),\nZepatier (elbasvir/grazoprevir)]\nb. HCV NS5A inh",
    "4A protease inhibitor [e.g., Incivek (teleprevir), Olysio (simeprevir),\nVictrelis (boceprevir), Viekira (dasabuvir/ombitasvir/ paritaprevir/ritonavir),\nZepatier (elbasvir/grazoprevir)]\nb. HCV NS5A inhibitor [e.g., Daklinza (daclatasvir), Epclusa (sofosbuvir/velpatasvir),\nHarvoni (ledipasvir/sofosbuvir), Viekira (dasabuvir/ombitasvir/\nparitaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\nb. Patient has compensated cirrhosis (Child-Pugh A)\nc. Patient is a liver or kidney transplant recipient\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 16 weeks.\nE. For the treatment of chronic hepatitis C genotype 1 infection in patients who are treatment-\nexperienced with an NS5A inhibitor without prior treatment with an NS3/4A protease\ninhibitor, who are without cirrhosis or have compensated cirrhosis, or is a liver or kidney\ntransplant recipient, Mavyret will be approved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. Patient has prior treatment experience with an HCV NS5A inhibitor [e.g., Daklinza\n(daclatasvir), Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir)]. This\ndoes not include combination products also containing an NS3/4A inhibitor [e.g.,\nViekira (dasabuvir/ombitasvir/paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)].\n-AND-\n3. Patient has no prior treatment experience with an NS3/4A protease inhibitor [e.g.,\nIncivek (teleprevir), Olysio (simeprevir), Victrelis (boceprevir), Viekira\n(dasabuvir/ombitasvir/ paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n© 2024 UnitedHealthcare Services Inc.\n4\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\nb. Patient has compensated cirrhosis (Child-Pug",
    "evir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n© 2024 UnitedHealthcare Services Inc.\n4\n-AND-\n4. One of the following:\na. Patient is without cirrhosis\nb. Patient has compensated cirrhosis (Child-Pugh A)\nc. Patient is a liver or kidney transplant recipient\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 16 weeks.\nF. For the treatment of chronic hepatitis C genotype 1 in patients who are treatment-\nexperienced with an NS3/4A protease inhibitor without prior treatment with an NS5A\ninhibitor, who are without cirrhosis or have compensated cirrhosis, Mavyret will be\napproved based on all of the following criteria:\n1. Diagnosis of chronic hepatitis C genotype 1 infection\n-AND-\n2. Patient has prior treatment experience with an NS3/4A protease inhibitor [e.g., Incivek\n(teleprevir), Olysio (simeprevir), Victrelis (boceprevir)]. This does not include\ncombination products also containing an NS5A inhibitor [e.g., Viekira\n(dasabuvir/ombitasvir/ paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)].\n-AND-\n3. Patient has no prior treatment experience with an HCV NS5A inhibitor [e.g., Daklinza\n(daclatasvir), Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Viekira\n(dasabuvir/ombitasvir/ paritaprevir/ritonavir), Zepatier (elbasvir/grazoprevir)]\n-AND-\n4. One of the following:\na. Patient is without cirrhosis.\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n5. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n© 2024 UnitedHealthcare Services Inc.\n5\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 12 weeks.\nG. For treatment of hepatitis C genotype 1, 2, 3, 4, 5, and 6 in liver or kidne",
    "itedHealthcare Services Inc.\n5\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 12 weeks.\nG. For treatment of hepatitis C genotype 1, 2, 3, 4, 5, and 6 in liver or kidney transplant\nrecipients who are without cirrhosis or have compensated cirrhosis, Mavyret will be\napproved based on all of the following criteria:\n1. Diagnosis of hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection\n-AND-\n2. One of the following:\na. Patient is a liver transplant recipient\nb. Patient is a kidney transplant recipient\n-AND-\n3. One of the following:\na. Patient is without cirrhosis\n-OR-\nb. Patient has compensated cirrhosis (Child-Pugh A)\n-AND-\n4. Patient is not receiving Mavyret in combination with another HCV direct acting antiviral\nagent [e.g., Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir), Sovaldi\n(sofosbuvir), Zepatier (elbasvir/grazoprevir)]\nAuthorization will be issued for 12 weeks.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place\n• Medical necessity may be in place.\n© 2024 UnitedHealthcare Services Inc.\n6\n4. References:\n1. Mavyret [package insert]. North Chicago, IL: AbbVie Inc.; October 2023.\n2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of\nAmerica. Recommendations for Testing, Managing, and Treating Hepatitis C. Accessed July 9,\n2024.\nProgram Prior Authorization/Notification – Mavyret (glecaprevir/pibrentasvir)\nChange Control\nDate Change\n9/2017 New program.\n11/2018 Annual review with no chan",
    "ting Hepatitis C. Accessed July 9,\n2024.\nProgram Prior Authorization/Notification – Mavyret (glecaprevir/pibrentasvir)\nChange Control\nDate Change\n9/2017 New program.\n11/2018 Annual review with no changes to clinical criteria. Updated references.\n11/2019 Annual review. Updated treatment duration for treatment naïve patients\nwith cirrhosis based on updated labeling. Updated background and\nreferences.\n3/2020 Updated criteria to include treatment for liver and kidney transplant\nrecipients. Updated background and references.\n3/2021 Annual review with no changes to clinical criteria. Updated references.\n8/2021 Updated background with no changes to clinical criteria. Updated\nreferences.\n8/2022 Annual review. Updated coverage criteria for liver or kidney transplant\nrecipients per prescribing information. Updated references.\n8/2023 Annual review with no changes to coverage criteria.\n8/2024 Annual review with no changes to coverage criteria. Updated\nreferences.\n© 2024 UnitedHealthcare Services Inc.\n7"
  ]
}